Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
Introduction: Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of b...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2025-01-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18946 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148002215231488 |
|---|---|
| author | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Boon Hwa Tng Thevesh Thevananthan Kalaiarasu M Peariasamy Sheamini Sivasampu |
| author_facet | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Boon Hwa Tng Thevesh Thevananthan Kalaiarasu M Peariasamy Sheamini Sivasampu |
| author_sort | Masliyana Husin |
| collection | DOAJ |
| description |
Introduction: Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of booster vaccination against severe COVID-19 outcomes is crucial during the transition to endemicity.
Methodology: We conducted a population-based, matched case-control study in Malaysia to estimate the marginal vaccine effectiveness (mVE) of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against COVID-19 related intensive care unit (ICU) admission and death in Delta-predominant and Omicron-predominant periods.
Results: Receipt of a booster vaccination – either homologous or heterologous for CoronaVac, and homologous for BNT162b2 – demonstrated mVE estimates of at least 70% against ICU admission and at least 80% against death, compared to BNT162b2 primary vaccination, in both periods. Overall, the mVE estimates were 10–20 percentage points lower in the Omicron-predominant period than in the Delta-predominant period.
Conclusions: Our study reaffirms that the administration of booster vaccination increases protection against severe COVID-19 outcomes for BNT162b2 and CoronaVac primary vaccination recipients.
|
| format | Article |
| id | doaj-art-167aeb09eab74d628cec59a8dfe27c22 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-167aeb09eab74d628cec59a8dfe27c222025-08-20T02:27:22ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802025-01-01190110.3855/jidc.18946Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomesMasliyana Husin0Peter Seah Keng Tok1Jing Lian Suah2Boon Hwa Tng3Thevesh Thevananthan4Kalaiarasu M Peariasamy5Sheamini Sivasampu6Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaDisease Control Division, Ministry of Health Malaysia, Putrajaya, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia Introduction: Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of booster vaccination against severe COVID-19 outcomes is crucial during the transition to endemicity. Methodology: We conducted a population-based, matched case-control study in Malaysia to estimate the marginal vaccine effectiveness (mVE) of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against COVID-19 related intensive care unit (ICU) admission and death in Delta-predominant and Omicron-predominant periods. Results: Receipt of a booster vaccination – either homologous or heterologous for CoronaVac, and homologous for BNT162b2 – demonstrated mVE estimates of at least 70% against ICU admission and at least 80% against death, compared to BNT162b2 primary vaccination, in both periods. Overall, the mVE estimates were 10–20 percentage points lower in the Omicron-predominant period than in the Delta-predominant period. Conclusions: Our study reaffirms that the administration of booster vaccination increases protection against severe COVID-19 outcomes for BNT162b2 and CoronaVac primary vaccination recipients. https://jidc.org/index.php/journal/article/view/18946SARS-CoV-2COVID-19vaccinesBNT162b2CoronaVacbooster |
| spellingShingle | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Boon Hwa Tng Thevesh Thevananthan Kalaiarasu M Peariasamy Sheamini Sivasampu Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes Journal of Infection in Developing Countries SARS-CoV-2 COVID-19 vaccines BNT162b2 CoronaVac booster |
| title | Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes |
| title_full | Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes |
| title_fullStr | Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes |
| title_full_unstemmed | Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes |
| title_short | Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes |
| title_sort | effectiveness of homologous and heterologous bnt162b2 and coronavac booster vaccination against severe covid 19 outcomes |
| topic | SARS-CoV-2 COVID-19 vaccines BNT162b2 CoronaVac booster |
| url | https://jidc.org/index.php/journal/article/view/18946 |
| work_keys_str_mv | AT masliyanahusin effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT peterseahkengtok effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT jingliansuah effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT boonhwatng effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT theveshthevananthan effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT kalaiarasumpeariasamy effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes AT sheaminisivasampu effectivenessofhomologousandheterologousbnt162b2andcoronavacboostervaccinationagainstseverecovid19outcomes |